Jaguar Health (JAGX) Net Income towards Common Stockholders (2014 - 2026)
Jaguar Health (JAGX) posted quarterly Net Income towards Common Stockholders of -$7.0 million for Q1 2026, up 32.96% year-over-year from -$5.3 million in Q1 2025, and up 69.75% quarter-over-quarter from -$23.2 million in Q4 2025.
Jaguar Health (JAGX) Net Income towards Common Stockholders (2014 - 2026) Analysis & Trends
Jaguar Health (JAGX) has reported Net Income towards Common Stockholders for 13 consecutive years, with -$7.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 32.96% year-over-year to -$7.0 million; the TTM figure through Mar 2026 stood at -$50.4 million (down 25.38% YoY), while the FY2025 annual figure was -$53.6 million, down 39.18% from the prior year.
- Net Income towards Common Stockholders rose to -$7.0 million in Q1 2026 per JAGX's latest filing, from -$23.2 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$7.0 million in Q1 2026 and bottomed at -$23.2 million in Q4 2025.
- Historically, Net Income towards Common Stockholders has averaged -$11.1 million across 5 years, with a median of -$10.0 million in 2024.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders jumped 47.03% — and 2025, when it slumped 126.63%.
- Jaguar Health's Net Income towards Common Stockholders stood at -$7.6 million in 2022, then retreated by 20.96% to -$9.2 million in 2023, then dropped by 11.6% to -$10.2 million in 2024, then plunged by 126.63% to -$23.2 million in 2025, then soared by 69.75% to -$7.0 million in 2026.
- Business Quant data shows JAGX's Net Income towards Common Stockholders at -$7.0 million in Q1 2026, -$23.2 million in Q4 2025, and -$9.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Jaguar Health | 447,549.24 | -9.62 Mn | 19.11 Mn | -7.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.02 Mn |
| Dec 31, 2025 | -23.19 Mn |
| Sep 30, 2025 | -9.65 Mn |
| Jun 30, 2025 | -10.56 Mn |
| Mar 31, 2025 | -10.46 Mn |
| Dec 31, 2024 | -10.23 Mn |
| Sep 30, 2024 | -10.02 Mn |
| Jun 30, 2024 | -9.49 Mn |
| Mar 31, 2024 | -9.23 Mn |
| Dec 31, 2023 | -9.17 Mn |
| Sep 30, 2023 | -7.78 Mn |
| Jun 30, 2023 | -12.15 Mn |
| Mar 31, 2023 | -12.20 Mn |
| Dec 31, 2022 | -7.58 Mn |
| Sep 30, 2022 | -12.52 Mn |
| Jun 30, 2022 | -9.37 Mn |
| Mar 31, 2022 | -17.99 Mn |
| Dec 31, 2021 | -14.31 Mn |
| Sep 30, 2021 | -12.19 Mn |
| Jun 30, 2021 | -14.08 Mn |